CN116194141A - 具有egfr突变的非小细胞肺癌的治疗 - Google Patents

具有egfr突变的非小细胞肺癌的治疗 Download PDF

Info

Publication number
CN116194141A
CN116194141A CN202180052496.5A CN202180052496A CN116194141A CN 116194141 A CN116194141 A CN 116194141A CN 202180052496 A CN202180052496 A CN 202180052496A CN 116194141 A CN116194141 A CN 116194141A
Authority
CN
China
Prior art keywords
egfr
cancer
seq
met
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052496.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·诺布劳奇
S·穆尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN116194141A publication Critical patent/CN116194141A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202180052496.5A 2020-08-25 2021-08-25 具有egfr突变的非小细胞肺癌的治疗 Pending CN116194141A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069748P 2020-08-25 2020-08-25
US63/069748 2020-08-25
PCT/IB2021/057794 WO2022043895A2 (en) 2020-08-25 2021-08-25 Treatment of non-small lung cancer with egfr mutations

Publications (1)

Publication Number Publication Date
CN116194141A true CN116194141A (zh) 2023-05-30

Family

ID=80352814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052496.5A Pending CN116194141A (zh) 2020-08-25 2021-08-25 具有egfr突变的非小细胞肺癌的治疗

Country Status (11)

Country Link
US (2) US12528869B2 (cg-RX-API-DMAC10.html)
EP (1) EP4204455A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023539589A (cg-RX-API-DMAC10.html)
KR (1) KR20230053686A (cg-RX-API-DMAC10.html)
CN (1) CN116194141A (cg-RX-API-DMAC10.html)
AU (1) AU2021330539A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192922A1 (cg-RX-API-DMAC10.html)
IL (1) IL300854A (cg-RX-API-DMAC10.html)
JO (1) JOP20230039A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002362A (cg-RX-API-DMAC10.html)
WO (1) WO2022043895A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174677A1 (en) * 2021-11-16 2023-06-08 Janssen Biotech, Inc. Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL)
CN119790073A (zh) * 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
WO2024108193A2 (en) * 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent
CN116284335A (zh) * 2023-03-17 2023-06-23 云南中医药大学 Egfr基因突变体的检测方法及应用
WO2025158277A1 (en) * 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2832971C (en) 2011-04-15 2016-04-12 Esco Corporation Replaceable wear parts for an earth-working roll
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
WO2020102647A1 (en) 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
IL305700A (en) 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations

Also Published As

Publication number Publication date
JOP20230039A1 (ar) 2023-02-23
WO2022043895A8 (en) 2023-03-09
CA3192922A1 (en) 2022-03-03
AU2021330539A1 (en) 2023-05-04
US20260070993A1 (en) 2026-03-12
AU2021330539A9 (en) 2023-07-13
EP4204455A4 (en) 2024-10-16
MX2023002362A (es) 2023-05-19
WO2022043895A2 (en) 2022-03-03
US12528869B2 (en) 2026-01-20
WO2022043895A3 (en) 2022-06-09
EP4204455A2 (en) 2023-07-05
JP2023539589A (ja) 2023-09-15
IL300854A (en) 2023-04-01
KR20230053686A (ko) 2023-04-21
US20220064306A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
US20260125480A1 (en) Bispecific EGFR/C-Met Antibodies
US12528869B2 (en) Treatment of non-small cell lung cancer with EGFR mutations
CN106999583A (zh) 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
CN106102774A (zh) 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
US20250257139A1 (en) Use of Amivantamab to Treat Colorectal Cancer
KR20220140794A (ko) c-MET 엑손 14 스킵핑 돌연변이를 갖는 환자의 치료
CN121194785A (zh) 用于治疗非小细胞肺癌（nsclc）的方法
KR20140130455A (ko) Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
EP4476255A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CN117716050A (zh) 用于鉴定进行组合治疗的癌症患者的方法
CN120882752A (zh) 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法
US20220298248A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
US20240228634A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
HK40116078A (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
HK40104478A (en) Methods for identifying cancer patients for combination treatment
HK40108897A (en) Use of amivantamab to treat colorectal cancer
CN118679186A (zh) 用于减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法
CN118414167A (zh) 埃万妥单抗用于治疗结肠直肠癌的用途
EA050641B1 (ru) Лечение раковых заболеваний без активирующих мутаций egfr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination